Haemonetics Corp (HAE)
85.19
-0.31
(-0.36%)
USD |
NYSE |
Jun 21, 16:00
85.20
+0.01
(+0.01%)
Pre-Market: 20:00
Haemonetics Research and Development Expense (Annual): 54.44M for March 31, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| March 31, 2024 | 54.44M |
| March 31, 2023 | 50.13M |
| March 31, 2022 | 46.80M |
| March 31, 2021 | 32.86M |
| March 31, 2020 | 30.88M |
| March 31, 2019 | 35.71M |
| March 31, 2018 | 39.23M |
| March 31, 2017 | 37.56M |
| March 31, 2016 | 44.96M |
| March 31, 2015 | 54.19M |
| March 31, 2014 | 54.20M |
| March 31, 2013 | 44.39M |
| March 31, 2012 | 36.80M |
| March 31, 2011 | 32.66M |
| March 31, 2010 | 26.38M |
| March 31, 2009 | 23.86M |
| Date | Value |
|---|---|
| March 31, 2008 | 24.32M |
| March 31, 2007 | 23.88M |
| March 31, 2006 | 26.52M |
| March 31, 2005 | 19.99M |
| March 31, 2004 | 17.40M |
| March 31, 2003 | 19.51M |
| March 31, 2002 | 19.51M |
| March 31, 2001 | 19.04M |
| March 31, 2000 | 14.94M |
| March 31, 1999 | 15.15M |
| March 31, 1998 | 17.90M |
| March 31, 1997 | 18.60M |
| March 31, 1996 | 18.50M |
| March 31, 1995 | 16.70M |
| March 31, 1994 | 15.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
30.88M
Minimum
2020
54.44M
Maximum
2024
43.02M
Average
46.80M
Median
2022
Research and Development Expense (Annual) Benchmarks
| ResMed Inc | 287.64M |
| Boston Scientific Corp | 1.414B |
| Stryker Corp | 1.388B |
| InfuSystems Holdings Inc | -- |
| Perspective Therapeutics Inc | 21.31M |